Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Back to Journals Drug Design, Development and Therapy Volume 19 The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review Authors Liu Z, Yu S, Jin X, Sheng L, YanMu MR, Gao J, Lu J, Lei T Received 11 August 2025 Accepted for publication 15 November 2025 Published 22 November 2025 Volume 2025:19 Pages 1038310409 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Professor Anastasios Lymperopoulos Zhao Liu, 1 Shanshan Yu, 1 Xinyan Jin, 1 Luguang Sheng, 2 Mai Re YanMu, 1 Jie Gao, 1 Jun Lu, 1 Tao Lei 1 1 Department of Endocrinology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Peoples Republic of China
The Three Patent Cliff Waves: The US market $20+ billion in annual GLP-1 sales and counting stays protected until at least 2031
However, deletion of lncRNA UCA1 decreases the levels of TNF-, IL-6 and IL-1 and reduces the apoptosis of intestinal epithelial cells, suggesting that knockdown of lncRNA UCA1 may alleviate the symptoms of UC
Just stuck." - u/KeepTryingAnyway "I hit a wall around week 12
Nevertheless, a study conducted on the LITMUS consortium European suggested that 98% of the current registry cohort of patients with NAFLD would meet the new criteria for MASLD [52]
Neuropeptides 38, 175188
US$ 25.11
US$ 27.15
US$ 25.27
US$ 26.31
US$ 22.59
